Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Aromatase inhibitors and tamoxifen: where do we go from here?

Nature Clinical Practice Oncology volume 4, pages 626–627 (2007)Cite this article

boxed-textCoates AS et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486–492

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Coates AS et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486–492

    Article  CAS  Google Scholar 

  2. Buzdar AU and Cuzick J (2006) Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res 12 (Suppl): S1037–S1048

    Article  Google Scholar 

  3. Jin Y et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97: 30–39

    Article  CAS  Google Scholar 

  4. Goetz MP et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312–9318

    Article  CAS  Google Scholar 

  5. Goetz MP et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101: 113–121

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. MP Goetz is an Assistant Professor of Oncology and CL Loprinzi is a Professor of Oncology at the Mayo Clinic College of Medicine, Rochester, MN, USA.,

    Matthew P Goetz & Charles L Loprinzi

Authors
  1. Matthew P Goetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles L Loprinzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew P Goetz.

Ethics declarations

Competing interests

Dr Goetz is a co-inventor on a pending patent application that is owned by the Mayo Foundation for Medical Education and Research and is related to the use of CYP2D6 as a predictor of recurrence in tamoxifen-treated breast cancer. Dr Goetz reports that he is a consultant to Roche and DNA Direct.

CL Loprinzi declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goetz, M., Loprinzi, C. Aromatase inhibitors and tamoxifen: where do we go from here?. Nat Rev Clin Oncol 4, 626–627 (2007). https://doi.org/10.1038/ncponc0955

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0955

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing